|Bid||31.26 x 1200|
|Ask||31.61 x 1000|
|Day's Range||30.98 - 31.38|
|52 Week Range||26.03 - 44.18|
|Beta (3Y Monthly)||1.69|
|PE Ratio (TTM)||29.83|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.67|
HERTFORDSHIRE, England and PITTSBURGH , Feb. 22, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, ...
The tide is turning. Goldman Sachs is now calling an end to an investing strategy it first recommended two years ago."For the past two years we have consistently advocated buying strong balance sheet stocks, but we believe the risk-reward has shifted in favor of closing this recommendation," Goldman Sachs' equity strategist David Kostin wrote on Feb. 8. "We no longer recommend strong balance sheets."These "strong balance sheet" stocks include major names like Facebook (NASDAQ:FB), Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) and Costco (NASDAQ:COST). So far this strategy has done very well for investors. Goldman Sachs' basket of 50 strong balance sheet stocks outperformed weak balance sheet stocks by 25 percentage points since early 2017.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever the Federal Reserve's recent dovish commentary indicates that the hiking cycle may have come to an end. This should ease pressure on corporate balance sheets -- leading Kostin to say: "Our recent research showed that strong balance sheets are among the worst performing factors during the 12 months following the end of Fed hiking cycles, when U.S. Treasury yields typically also decline." * 7 Healthy Dividend Stocks to Buy for Extra Stability Plus the firm's optimistic outlook for the economy is also a boost to weaker balance sheet stocks. Investors tend to rotate to strong balance sheet stocks in times of weak or decelerating economic growth. So which stocks should you be looking at now? Here are six stocks from the firm's weak balance sheet basket. I also use TipRanks' data to see what the analysts are saying about these picks.Let's take a closer look now: Stocks To Buy: Delta Airlines (DAL)Despite the government shutdown costing Delta Air Lines (NYSE:DAL) $25 million in revenue for January, this stock still gets the thumbs up from the Street.The airline carrier recently reported fourth-quarter earnings that beat expectations thanks to strong travel demand. Delta's total revenue rose to $10.74 billion during Q4, up 5% year-over-year."2018 was a successful year for Delta with record operational reliability, increasing customer satisfaction, and solid financial results in the face of higher fuel costs" said CEO Ed Bastian. "As we move into 2019, we expect to drive double-digit earnings growth through higher revenues, maintaining a cost trajectory below inflation, and the modest benefit from lower fuel costs."As Tigress Financial's Ivan Feinseth (Track Record & Ratings) notes, a strong economy, low unemployment and increases in consumer spending are driving record levels of airline travel.That's reflected in the company's strong buy consensus and 21% upside potential.Want to learn more about Delta? Get the free DAL Stock Research Report. AT&T (T)AT&T (NYSE:T) is a leading provider of IP, broadband, video and wireless services. And through its recent Time Warner acquisition it is now a top-four producer of content globally.2019 is about positioning for better services growth in 2020 and beyond, says Oppenheimer's Timothy Horan (Track Record & Ratings). Horan, like most of the Street, currently has a buy rating on T stock. His bullish call comes with a $41 price target for 38% upside potential.T stock has the ability to integrate its services in unique ways and hassubstantial room to use virtualized technologies to greatly reduce operating and capital expenditures. "We believe that combined with TWX, FCF/share could grow 6% per year" writes the analyst. * 10 Smart Money Stocks to Buy Now Overall, T has a strong buy consensus with 11 buy ratings vs just three hold ratings. Get the T Stock Research Report. Mylan (MYL)If you haven't heard of Mylan NV (NASDAQ:MYL) before, listen up. This is a global healthcare company making high quality medicines available to everyone who needs them. In fact, Mylan is the U.S.'s second largest provider of prescription medicine with over 650 different products, including the EpiPen.One product in particular is generating attention right now. That's asthma drug Advair. "Long awaited generic Advair approval comes and at a key time" cheered RBC Capital's Randall Stanicky (Track Record & Ratings) recently. While overdue, MYL received FDA approval for its generic Advair (Wixela Inhub) on Jan. 30. Shares jumped 7% on the news.Stanicky has a buy rating on the stock with a $50 price target, suggesting 56% upside lies ahead. "MYL remains one of the 'cheapest' generic stocks" enthuses the analyst. That's because its high-value pipeline comes with push-back over (i) low P&L visibility and (ii) governance concerns.That said, valuation is very compelling with multiple catalysts that could surprise to the upside. Bottom line: "Stronger remaining core base combined with emerging complex generic pipeline should position shares for an upward move."However not all analysts are so positive. The Street is currently divided between buy and hold ratings. Get the MYL Stock Research Report. CBS Corp (CBS)Even though mass media stock CBS Corporation (NYSE:CBS) just reported a Q4 earnings miss, analysts are staying firmly on side. From top analysts the consensus remains a strong buy. Plus, CBS shares are up 15% since the beginning of this year.Top Barrington Research analyst James Goss (Track Record & Ratings) has reiterated his CBS buy rating with a $72 price target. That indicates compelling upside potential of 41%. "We view CBS as one of our best value media ideas" Goss writes.While the lack of syndication deals was largely known going into the quarter, Goss believes consensus had failed to adjust estimates for this high-margin revenue stream. The result: a roughly $100 million revenue and 3-cent EPS miss.But even so, CBS has just announced that it has hit its 8 million OTT subscriber goal. Prepare yourselves, because this is about two years ahead of schedule. * 7 Financial Stocks With Accelerating Growth "At this point, even with the uncertainty at the top and the potential for M&A, CBS trades at a paltry 7x 2019E OIBDA, at a discount to our broadcast affiliate peer group despite owning better stations and all of the content, plus a thriving OTT business" concludes the analyst. Get the CBS Stock Research Report. General Motors (GM)"Motoring into 2019" cheers RBC Capital's Joseph Spak (Track Record & Ratings). He made the comment following the General Motors Company's (NYSE:GM) solid 4Q18 earnings results.The details of the quarter -- which were strong -- should lead investors to have more confidence in 2019 EPS says Goss. For example, management guided the tax rate to 16%-18% versus the expected 20%.Plus the analyst continues to view GM's transformation as underappreciated. "Recent restructuring actions that should lead to ~$4.5bn savings run-rate in 2020 significantly improves GM's positioning" he writes.And it seems like the Street agrees. If we zero in on top-performing analysts, we can see GM holds only buy ratings right now. Get the GM Stock Research Report. Allergen (AGN)Botox maker Allergan (NYSE:AGN) is one the highest-quality companies in the Pharma industry. It is also one of the most-innovative. Allergan is currently advancing a number of key pipeline products through late stage clinical trials, including new oral drugs for migraine, rapastinel for major depressive disorder and CVC for NASH.However shares have underperformed, with prices sinking 15% in the last year. That's down to a disappointing revenue outlook for 2019 and increasing competition for drugs including botox.Plus billionaire hedge fund manager David Tepper is now suggesting the company should sell itself. His Appaloosa hedge fund owns 1.5 million shares in AGN -- down 842,591 shares from Q3. So far Allergan has refused Tepper's suggestion to split the chairman and CEO roles, currently held by Brent Saunders.However, analysts still see a buying opportunity at hand. Mizuho Securities' Irina Rivkind Koffler (Track Record & Ratings) is a top-rated analyst according to TipRanks. She has a buy rating on the stock with a $200 price target. That indicates 45% upside potential from current levels. Koffler cites the company's 4Q18 top and bottom-line beat, down to better Restasis durability, share buybacks and strong injectables. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? "We valued AGN solely via DCF analysis of 2018-2025 cash flows. We utilize a weighted average cost of capital of 11% and a 3% terminal growth rate. This analysis generates a valuation of $213 per share, and supports our Buy rating" explains the analyst. Get the AGN Stock Research Report.TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Smart Money Stocks to Buy Now * The 10 Best Cheap Stocks to Buy Right Now * 7 Restaurant Stocks to Watch in 2019 Compare Brokers The post 6 Hot Stocks For Goldman Sachs' New Investing Strategy appeared first on InvestorPlace.
Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its GA Depot, a novel long-acting depot formulation of glatiramer acetate for relapsing forms of Multiple Sclerosis (RMS) and for primary progressive multiple sclerosis (PPMS), as well as new horizon treatments for MS on Tuesday, March 5th, 12 noon – 1:30 pm Eastern Time, in New York City. The meeting will feature a presentation by Carlo Tornatore, MD, Georgetown University Medical Center, who will discuss the current treatment landscape, as well as the unmet medical need for treating patients with PPMS. Dr. Tornatore will be available to answer questions at the conclusion of the event.
Shares of Biogen Inc. fell 1.2% in premarket trade Thursday after the stock was downgraded to hold from buy by Stifel, with analysts citing "decreased confidence in Alzheimer's, a looming Tecfidera legal saga and well-documented competitive threats to Spinraza." Stifel also lowered its price target to $346 from $397. Investor confidence in the Alzheimer's space took a hit last month after Roche Holding AG announced it was stopping clinical trials for two Alzheimer's drugs targeting beta-amyloid, a key marker of the disease. The announcement turned up the pressure on Biogen, which is currently working a drug that also targets beta-amyloid. Earlier this month, the U.S. Patent and Trademark Office said Mylan N.V. would likely succeed in a patent challenge against Biogen's top-selling multiple sclerosis drug Tecfidera, raising concerns about the drug's exclusivity and future sales estimates. Biogen also faces looming competition to its spinal muscular atrophy drug, Spinraza, including Roche's risdiplam and Novartis's branaplam. The company "has become a harder story for us to get behind with optimism and conviction," Stifel analysts wrote. Shares of Biogen have gained 17% in the past 12 months, while the S&P 500 has gained 3%.
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.
The U.S. Supreme Court on Tuesday rejected Maryland's bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs. The justices declined to take up Maryland's appeal of a 2018 federal appeals court ruling that struck down the state's law, That ruling held that Maryland had regulated wholesale pricing by the companies in violation of the U.S. Constitution's bar on state-level regulation of interstate commerce.
Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to claim about 25 percent of the U.S. market by the end of the year, CEO Kare Schultz said on Tuesday, as the company closes in on a return to growth in 2020. Wall Street has viewed the EpiPen rival as a welcome profit-booster for Teva as it contends with declining U.S. margins for its older generic medicines, competition for multiple sclerosis treatment Copaxone and costly acquisitions.
Is Teva Pharmaceutical an Attractive Pick This February?Stock price movementsOn February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower
Announcement: Moody's announces completion of a periodic review of ratings of Mylan N.V. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Mylan N.V. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY
The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said. Advair targets certain patients with asthma or chronic obstructive pulmonary disease and brought in revenue of about $4.19 billion in 2017 for the London-listed GSK. Mylan received approval for the treatment from the U.S. Food and Drug Administration last month.
HERTFORDSHIRE, England and PITTSBURGH, Feb. 12, 2019 /PRNewswire/ -- Mylan N.V. (MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of ADVAIR DISKUS®, Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), approved by the U.S. Food and Drug Administration (FDA) through the Abbreviated New Drug Application (ANDA) pathway. Wixela Inhub is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). All three strengths of Wixela Inhub will be offered at a wholesale acquisition cost* 70% less than ADVAIR DISKUS and 67% less than GSK's authorized generic version which launched on Feb. 8.
HERTFORDSHIRE, England , and PITTSBURGH , Feb. 11, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2018 ...
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday. More than 763,000 tablets of the drug Amvalo, manufactured from April to July in Mylan Laboratories Limited in India, are the subject of recall, Pfizer Japan Inc said in a statement, adding there were no reports of any damage to health. "We will fully pay careful attention to our manufacturing and quality control to prevent a recurrence," Pfizer Japan President Akihisa Harada said.
Mylan NV NASDAQ/NGS:MYLView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MYL totaled $17.51 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Biogen will likely prevail in a patent challenge from Mylan for its multiple sclerosis treatment Tecfidera, several analysts said this week, though Biogen stock stumbled in Thursday trades.
Overall, the stock market has made a huge improvement at the start of 2019 from where it ended in 2018; it has been a complete turnaround from last year's drop when markets entered bear market territory. But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have had this luxury. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy … it has just become a little trickier to find them amid all the flashy comeback stories.To find the best stocks to invest in now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the backburner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, the best undervalued stocks to invest in are those that dropped by double-digit percentages during the current rally.Why is that?InvestorPlace - Stock Market News, Stock Advice & Trading TipsMarkets that are pricing in the negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 10 Monster Growth Stocks to Buy for 2019 and Beyond With all of that in mind, here are five undervalued stocks to invest in that aren't as scary as they seem.Source: Dalvenjah via Flickr Sony (SNE)Investors expected more from Sony's (NYSE:SNE) earnings report when the company posted results on Feb. 1. Revenue of 2.4 trillion yen in the third-quarter missed estimates for 2.67 trillion yen.Adding salt to the wound, many SNE investors are fretting over Sony's weaker sales outlook, with smartphone and camera sales lagging. On the flipside, the PlayStation 4 business still could rebound. Even though the console cycle is many years old, customers will continue to buy new game titles. And in the smartphone space, a refresh in the second half of this year may give customers a reason to buy a new Sony device again.Sony is clearly not a broken company, so the stock's drop from $50 on Feb. 1 to $46.29 appears overdone. At just 4% above its yearly lows and a whopping 24% below its 52-week high, which SNE set just a few months ago, Sony stock clearly deserves its spot among the best undervalued stocks to consider now.Source: Shutterstock Celestica (CLS)Celestica (NYSE:CLS) reported fourth-quarter revenue of $1.73 billion, up 10% from last year. Net earnings rose $46.5 million to $60.1 million, bringing in earnings of 44 cents a share. However, investors were unimpressed with the weak sequential revenue in its Communications, ATS and CCS segments, which were either flat or down. Still, revenue from all segments grew in the double digits from last year.Celestica ended the year with $422 million in cash and cash equivalents. Net cash fell $335 million for the year. And the balance sheet is not as strong as it could be, with non-IFRS debt leverage at 2.6X.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line. * 7 Semiconductor Stocks to Watch After falling 16% in the last week, Celestica stock is an undervalued play worth considering.Source: Everjean via Flickr Allergan (AGN)Generic drug supplier Allergan (NYSE:AGN) recently fell 12.8% for two reasons. First, its fourth-quarter earnings report did not please investors. Earnings-per-share came in at $4.29 (non-GAAP) while revenue fell 5.8% to $4.08 billion. With GAAP down $12.83 a share, its big difference from non-GAAP is scaring off investors. Allergan's accounting does not show any transparency in the health of the business.On Friday, Feb. 1, the Food and Drug Administration approved Evolus' (NASDAQ:EOLS) Jeuveau. This product competes directly with Allergan's Botox. Pricing could come in at 20% below that of Botox, putting pressure on Allergan's bottom line.Be warned: it's likely that AGN stock will continue to sell off as investors price in the worst case scenario for Botox. Even though management already expects some pricing erosion, it is confident that the sales volume will taper off slowly. But this is good news for iinvestors in search of a bargain, as the more the stock falls, the more discount value investors get on AGN stock.As Allergan launches new products this year, it will offset the negative impact of generic drug competition for Botox, making it an undervalued stock to watch.Source: Shutterstock Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose 17.5% weekly drop appears greatly overdone. The market all but erased the powerful uptrend in the stock that began after INVA sold off in November 2018 and bottomed at $14.The FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo; $51.7 million came from global net sales of Revar/Breo Ellipta.On Feb. 6, Innoviva reported revenue of $79.86 million, up 14.9% from last year. With the stock trading at a forward price-to-earnings ratio of 7.6, the price-earnings-to-growth ratio is 0.55. As such, this general pessimism has created an appealing entry point to INVA stock. * 10 Dividend Growth Stocks You Can't Miss Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to invest in now.Source: Shutterstock Vodafone (VOD)Telecom stocks are out of favor. Just look at Verizon (NYSE:VZ), which is down 12% from its yearly highs; AT&T (NYSE:T) is down 24% from its highs. But Vodafone (NASDAQ: VOD) is down the most, falling 43% from its 52-week highs.Third-quarter results for VOD missed analyst consensus sales forecasts. Vodafone continued to under-perform in Europe, due to rising competition. Although the company highlighted improving customer trends in Italy, Germany, and reduced churn in Spain, this was not enough to prevent revenue falling 5.6% in Europe and 6.8% overall.With all that bad news, it is little wonder why the stock has been marching lower. But VOD still has ways to mend the wound. The company could trim the dividend and re-allocate its resources toward advertising and capital expenditures. That would put it in a better position to compete with its European counterparts. And the stock would respond if those efforts lead to better revenue numbers.Vodafone shares pay a dividend yield in excess of 6%. This is higher than Verizon's 4.45% dividend yield but almost a point below AT&T's 6.8% rate. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Won Super Bowl Sunday * 7 High-Yield ETFs for Brave Investors * 10 F-Rated Stocks That Could Break Your Portfolio Compare Brokers The post 5 Undervalued Stocks to Invest In appeared first on InvestorPlace.
Mylan filled an inter partes review for Biogen's “514 patent,” the drug maker’s treatment patent on Tecfidera. The IPR was instituted on Wednesday.